Literature DB >> 17565831

[Construction of antisense human tankyrase-1 RNA retroviral vector and its inhibition on tongue cancer cells].

Yu-xin Ji1, Ping Zhang, Wei-min Chen, Sheng-rong Zhu, Xue-jin Tao.   

Abstract

OBJECTIVE: To investigate the inhibition of telomerase activity and cellular proliferation in tongue cancer TCCA-8113 cell lines by antisense human tankyrase-1 RNA treatment, and explore the possibility of the tankyrase-1 as a target of gene therapy for tongue cancer.
METHODS: The replication deficient retrovirus expressing tankyrase-1 antisense RNA was constructed to infect the TCCA-8113 cells. Tankyrase-1 expression was examined by RT-PCR. Telomerase activity was assayed by telomerase repeat amplification protocol (TRAP). Cell proliferation was investigated by cellular growth curve. Cellular apoptosis was detected by flow cytometry method and invert microscope.
RESULTS: Tankyrase-1 expression and telomerase activity of tongue cancer TCCA-8113 cells were significantly inhibited. There was G(1)-S phase arrest when TCCA-8113 cells were treated with antisense tankyrase-1 transduction. Cellular proliferation was arrested, and cellular apoptosis occurred after antisense tankyrase transduction.
CONCLUSIONS: The transduction of antisense tankyrase-1 by retroviral vector can significantly inhibit the tankyrase-1 expression and telomerase activity of tongue cancer TCCA-8113 cell lines, and arrest the cellular proliferation and promote cellular apoptosis. The tankyrase may be a potential target of gene therapy for tongue cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565831

Source DB:  PubMed          Journal:  Zhonghua Kou Qiang Yi Xue Za Zhi        ISSN: 1002-0098


  1 in total

1.  Knockdown of tankyrase 1 inhibits the progression of gastric adenocarcinoma via regulating human telomerase reverse transcriptase and telomeric repeat binding factor 1.

Authors:  Wei Liu; Ji-Jun Zhu; Yun-Yun Liu; Na-Na Tang; Yan Wang; Bo Jiang; Li-Li Wang; Yu-Xin Wang; Min-Peng Xie; Xiao-Yan Wang
Journal:  J Gastrointest Oncol       Date:  2022-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.